Courses

Updates on Therapeutic Strategies to Optimize Clinical Outcomes in Psoriatic Arthritis

Updates on Therapeutic Strategies to Optimize Clinical Outcomes in Psoriatic Arthritis

This CME program was derived from content presented at the Clinical Congress of Rheumatology 2018 annual meeting in Destin, Florida. The expert faculty, Drs. Alan L. Epstein and Anthony M. Turkiewicz, will review the pathogenesis of disease as well as joint symptoms for patients with active psoriatic arthritis (PsA). Controversies in the treatment and management of PsA along with rheumatoid ...
View Course
A Scientific Update of the Treatment of Multiple Sclerosis: Review of AAN 2018

A Scientific Update of the Treatment of Multiple Sclerosis: Review of AAN 2018

This CME/CNE program will highlight recent advances in the treatment and management of multiple sclerosis (MS) as presented at the 70th Annual American Academy of Neurology Meeting held in Los Angeles, California. The four expert faculty, led by Dr. Fred Lublin, will review the pathophysiology of MS as well as the mechanisms of action of current therapies. The role of ...
View Course
The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke

The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke

This CME/CNE program is derived from content presented at the National Lipid Association 2018 Scientific Sessions in Las Vegas, Nevada. The five expert faculty, led by Dr. Alan S. Brown, will review best practices for assessing the risk of cardiovascular disease (CVD). Recently released data, including the results of the ODYSSEY and FOURIER trials, will be outlined followed by a ...
View Course
Navigating the Role of PCSK9 Inhibitors in the Prevention of Cardiovascular Events

Navigating the Role of PCSK9 Inhibitors in the Prevention of Cardiovascular Events

This CME activity will review optimal treatment strategies and recent clinical trial data for patients with dyslipidemia, as presented at the American College of Cardiology 2018 in Orlando, Florida. Four expert faculty, led by Dr. Christopher Cannon, will analyze the science of LDL cholesterol and how it relates to cardiovascular events. Recent clinical trial data for PCSK9 inhibitors, including data ...
View Course
A Clinical Analysis of Optimal Therapeutics to Improve Outcomes in Patients with Advanced Prostate Cancer

A Clinical Analysis of Optimal Therapeutics to Improve Outcomes in Patients with Advanced Prostate Cancer

This CE program will analyze optimal therapeutics for the treatment and management of prostate cancer patients, incorporating data presented at the American Society of Clinical Oncology 2018 Genitourinary (GU) Cancers Symposium in San Francisco, California. The three expert faculty, led by Dr. Elisabeth Heath, will review the framework for clinical decision making in prostate cancer. Recent clinical trial data for ...
View Course
The Role of Oncolytic Viral Therapy in the Management of Patients With Metastatic Melanoma

The Role of Oncolytic Viral Therapy in the Management of Patients With Metastatic Melanoma

This CME/CE program will delve into the role of oncolytic viral therapy in the treatment and management of the metastatic melanoma patients, highlighting data presented at the Maui and Hawaii Dermatology 2018 annual meetings. The three expert faculty will review the immunotherapy for melanoma, followed by a discussion of recent safety and efficacy trial data for this emerging therapeutic option ...
View Course
Updated Therapeutic Strategies to Improve Outcomes in Patients with Breast Cancer

Updated Therapeutic Strategies to Improve Outcomes in Patients with Breast Cancer

This CME/CNE program will highlight recent advances in the treatment and management of breast cancer, as presented at the 40th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Three expert faculty will review the pathophysiology of breast cancer and the rationale for therapeutic choices. An evaluation of recent clinical trial data of current and emerging therapies will be ...
View Course
PCSK9 Inhibitor Therapeutics 2018: Analyses of Specific Patient Populations Data

PCSK9 Inhibitor Therapeutics 2018: Analyses of Specific Patient Populations Data

This educational program will explore and analyze data for PCSK9 inhibitor therapeutics in specific patient populations. Expert faculty will relay updates regarding recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at ...
View Course
The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options

The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options

The content for this activity is derived from a live symposium titled, “The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will focus on the role of lipoprotein(a) and its therapeutic options for patients with cardiovascular disease. A review of the ...
View Course
Applying Individualized Therapeutic Strategies of Switching and Sequencing to Improve Outcomes for Patients With Multiple Sclerosis

Applying Individualized Therapeutic Strategies of Switching and Sequencing to Improve Outcomes for Patients With Multiple Sclerosis

This content is derived from a CME symposium held in conjunction with the Advanced Curriculum for Multiple Sclerosis 2018 in San Diego, California. The five expert faculty will highlight individualized therapeutic strategies of switching and sequencing to improve outcomes for patients with multiple sclerosis (MS). Methods for predicating and monitoring disease therapy in the MS patient population will be reviewed ...
View Course